Clementia Pharmaceuticals Inc (NASDAQ:CMTA) – Analysts at Leerink Swann issued their FY2022 EPS estimates for shares of Clementia Pharmaceuticals in a research note issued to investors on Tuesday. Leerink Swann analyst J. Schwartz expects that the company will earn $1.35 per share for the year.
Other equities research analysts have also recently issued reports about the stock. Zacks Investment Research upgraded shares of Clementia Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, January 30th. Wedbush reiterated an “outperform” rating and set a $26.00 price objective on shares of Clementia Pharmaceuticals in a research report on Tuesday, November 14th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $27.00.
Clementia Pharmaceuticals (NASDAQ CMTA) traded down $0.70 during mid-day trading on Thursday, hitting $13.23. 105,439 shares of the stock traded hands, compared to its average volume of 120,074. Clementia Pharmaceuticals has a 12-month low of $11.72 and a 12-month high of $20.15.
Several institutional investors and hedge funds have recently bought and sold shares of the company. J. Goldman & Co LP acquired a new stake in shares of Clementia Pharmaceuticals during the fourth quarter worth $488,000. Driehaus Capital Management LLC increased its position in shares of Clementia Pharmaceuticals by 5.2% during the fourth quarter. Driehaus Capital Management LLC now owns 862,279 shares of the company’s stock worth $16,366,000 after buying an additional 42,771 shares during the period. Sectoral Asset Management Inc increased its position in shares of Clementia Pharmaceuticals by 148.5% during the fourth quarter. Sectoral Asset Management Inc now owns 75,313 shares of the company’s stock worth $1,429,000 after buying an additional 45,000 shares during the period. Alps Advisors Inc. acquired a new stake in shares of Clementia Pharmaceuticals during the fourth quarter worth $642,000. Finally, Victory Capital Management Inc. increased its position in shares of Clementia Pharmaceuticals by 12.7% during the fourth quarter. Victory Capital Management Inc. now owns 34,710 shares of the company’s stock worth $659,000 after buying an additional 3,920 shares during the period. Institutional investors own 73.82% of the company’s stock.
About Clementia Pharmaceuticals
Clementia Pharmaceuticals Inc is a clinical stage biopharmaceutical company. The Company is engaged in developing disease-modifying treatments for patients suffering from debilitating bone and other diseases with high unmet medical need. Its lead product candidate, palovarotene, is an oral small molecule that binds and activates retinoic acid receptor gamma (an RARg agonist), and has activity in preventing abnormal new bone formation as well as scar tissue formation (or fibrosis) in a variety of tissues in animal models.
Receive News & Ratings for Clementia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clementia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.